SARS-CoV-2 Spike RBD Neutralizing Antibody, monoclonal

• Catalog Number: orb1274211
• Category: Antibodies
• Description: SARS-CoV-2 Spike RBD Neutralizing Antibody, monoclonal
• Clonality: Recombinant
• Tested applications: ELISA, WB
• Reactivity: Human
• Isotype: Human IgG1/kappa
• Immunogen: Anti-SARS-CoV-2 RBD Neutralizing Antibody, Human IgG1 is isolated from a SARS-CoV-2 infected patient and is recombinantly produced from human 293 cells (HEK293). This antibody recognizes the SARS-CoV-2 Spike Protein RBD domain and inhibits the interaction between SARS-CoV-2 RBD and ACE2 with an IC50 of 1.47 ug/mL using SARS-CoV-2 Inhibitor Screening Kit .Pseudovirus assay shows that this antibody has potent neutralizing activity against pseudovirus bearing SARS-CoV-2 Spike protein.
• Concentration: batch dependent
• Form/Appearance: Lyophilized
• Conjugation: Unconjugated
• Target: S
• UniProt ID: P0DTC2
• Storage: For long term storage, the product should be stored at lyophilized state at -20°C or lower..Please avoid repeated freeze-thaw cycles.This product is stable after storage at:.-20 to -70°C for 12 months in lyophilized state from date of receipt;.-70°C for 3 months under sterile conditions after reconstitution.
• Buffer/Preservatives: Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4 . Normally trehalose is added as protectant before lyophilization.
• Alternative names: spike glycoprotein
• Note: For research use only
• Expiration Date: 12 months from date of receipt.

Anti-SARS-CoV-2 RBD Neutralizing Antibody, Human IgG1 on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

Serial dilutions of Anti-SARS-CoV-2 RBD Neutralizing Antibody, Human IgG1 was detected by SARS-CoV-2 Inhibitor screening Kit with a half maximal inhibitory concentration (IC50) of 1.472 ug/mL (QC tested).

Immobilized SARS-CoV-2 S1 protein, His Tag at 2 ug/mL (100 uL/well) can bind Anti-SARS-CoV-2 RBD Neutralizing Antibody, Human IgG1 with a linear range of 0.2-1.95 ng/mL (QC tested).

Serial dilutions of Anti-SARS-CoV-2 RBD Neutralizing Antibody, Human IgG1 was detected by Anti-SARS-CoV-2 Neutralizing Antibody Titer Serologic Assay Kit with a half maximal inhibitory concentration (IC50) of 0.6265 ug/mL (Routinely tested).

Serial dilutions of Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody was incubated with SARS-CoV-2 pseudotyped virus at 37C for 1 hour. Afterward, Huh-7 cells were added, followed by incubation at 37C for 24h. Chemiluminescence detection was performed and the virus neutralization titers (IC50) is 2.181 nM using the Reed-Muench method.

FACS analysis shows that the binding of SARS-CoV-2 S protein RBD, Mouse IgG2a Fc Tag to Vero E6 cells surface ACE2 was inhibited by increasing concentration of Anti-SARS-CoV-2 Neutralizing Antibody, Human IgG1. The concentration of SARS-CoV-2 S protein RBD used is 5 ug/ml. The IC50 is 10.33 ug/ml (Routinely tested).

FACS analysis shows that the binding of SARS-CoV-2 S1 protein, Mouse IgG2a Fc Tag to Vero E6 cells surface ACE2 was inhibited by increasing concentration of Anti-SARS-CoV-2 RBD Neutralizing Antibody, Human IgG1. The concentration of SARS-CoV-2 S1 protein used is 3 ug/ml. The IC50 is 1.352 ug/ml (Routinely tested).